Patheon signs up to manufacture Flexion's lead drug

Contract drugmaker Patheon inked a deal to manufacture Flexion Therapeutics' ($FLXN) top prospect as it moves through clinical development. The treatment, FX006, is an injectable steroid treatment for osteoarthritis pain, and its promise helped Flexion pull off a $60 million IPO last year. Under the latest agreement, Patheon will use its Swindon, U.K., site to manufacture doses of FX006 to support the drug's ongoing Phase III trial. More

Read more on